 The Seattle Times: CellCyte shares ride a wave of hype
For years, the founders of CellCyte Genetics relied on infusions from angel investors to keep their tiny startup afloat. But after Kirkland-based CellCyte...
 The Scotsman: A place for caution in research
WHO should decide what the limits are for science? That's the question raised by the Government's proposed revisions of the 1990 Human Fertilisation and Embryology Act, published last month.
The Scotsman: PPL collapse has 'dented confidence'
A LEADING life sciences expert said the collapse of PPL Therapeutics, creator of Dolly the cloned sheep, "severely dented" Scotland's biotech industry.
The Seattle Times: $12 million generated for Fate biotech, stem cell drugs
A group of venture capitalists is investing $12 million to launch Fate Therapeutics, a biotech company aiming to develop drugs that spur...
The Seattle Times: A time of turmoil for local biotechs
Failed tests and delays disappointed investors, but the region's industry is underpinned by major research institutions and robust VC activity, which is reason for optimism, observers say.
The Seattle Times: Seattle Genetics therapy trial encouraging
Seattle Genetics said Monday that its cancer therapy SGN-35 showed encouraging results in an early-stage clinical trial, boosting the strength...
The Seattle Times: Rival rips drug of Seattle biotech
A biotech rival has asked federal regulators not to approve ZymoGenetics' lead product, citing concerns about insufficient testing. The petitioner, King Pharmaceuticals...
The Seattle Times: Fungus infection killed Targeted Genetics patient
New details about the death of a patient in a Targeted Genetics clinical trial are steering suspicion away from the virus used to deliver...
The Seattle Times: Factories adapt in North Carolina town
Until the late 1950s, the low-slung brick building in the center of this minuscule town was home to the Kayser-Roth hosiery mill. Some 400 workers tended...
The Scotsman: Testing times for biotech champion
THE industry chief is fighting on various fronts in a bid to gain a healthy advantage for UK life sciences.
404 Not Found
404 Not Found
 301 Moved Permanently
404 Not Found
CMDB improves operating costs & security - Sponsored Link
Becton Dickinson's Q3 Revenues Rise 3 Percent on Bioscience Gains
Genekor to Distribute Rosetta Genomics' Assays
Biotech Stocks: AMAG, Covance slide on earnings reports
Sanofi to make formal Genzyme offer
Marina Biotech, Inc. Announces Upcoming Investor Conference Presentations
|
|
